Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

241 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genomic Landscape of Malignant Phyllodes Tumors Identifies Subsets for Targeted Therapy.
Bansal R, Adeyelu T, Elliott A, Tan AR, Ribeiro JR, Meisel J, Oberley MJ, Graff SL, Sledge GW Jr, Grilley-Olson JE, Sammons SL, Rosenberger LH. Bansal R, et al. Among authors: sledge gw jr. JCO Precis Oncol. 2024 Dec;8:e2400289. doi: 10.1200/PO.24.00289. Epub 2024 Dec 5. JCO Precis Oncol. 2024. PMID: 39637336 Free PMC article.
CYP2D6 activity in patients with metastatic breast cancer treated with single agent tamoxifen: results from ECOG-ACRIN E3108.
Stearns V, ONeill A, Schneider BP, Skaar TC, Liu MC, Lohrisch C, Goetz MP, Vallejos CS, Sparano JA, Villa D, Silverman P, Cheema PS, Moore DF Jr, Sledge GW Jr. Stearns V, et al. Among authors: sledge gw jr. Breast Cancer Res Treat. 2024 Oct 21. doi: 10.1007/s10549-024-07519-z. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39432161
Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
Chowdhury S, Xiu J, Ribeiro JR, Nicolaides T, Zhang J, Korn WM, Poorman KA, Lenz HJ, Marshall JL, Oberley MJ, Sledge GW Jr, Spetzler D, Kopetz S, Shen JP. Chowdhury S, et al. Among authors: sledge gw jr. Br J Cancer. 2024 Nov;131(8):1328-1339. doi: 10.1038/s41416-024-02826-0. Epub 2024 Sep 4. Br J Cancer. 2024. PMID: 39227409
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Parikh DA, Kody L, Brain S, Heditsian D, Lee V, Curtis C, Karin MR, Wapnir IL, Patel MI, Sledge GW Jr, Caswell-Jin JL. Parikh DA, et al. Among authors: sledge gw jr. Breast Cancer Res Treat. 2022 Jul;194(1):171-178. doi: 10.1007/s10549-022-06611-6. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35538268 Free PMC article.
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW Jr. Neven P, et al. Among authors: sledge gw jr. Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2. Breast Cancer Res. 2021. PMID: 34425869 Free PMC article. Clinical Trial.
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Gordon MS, Nemunaitis J, Barve M, Wainberg ZA, Hamilton EP, Ramanathan RK, Sledge GW Jr, Yue H, Morgan-Lappe SE, Blaney M, Kasichayanula S, Motwani M, Wang L, Naumovski L, Strickler JH. Gordon MS, et al. Among authors: sledge gw jr. Mol Cancer Ther. 2021 Oct;20(10):1988-1995. doi: 10.1158/1535-7163.MCT-20-0985. Epub 2021 Jul 26. Mol Cancer Ther. 2021. PMID: 34315767 Free PMC article. Clinical Trial.
241 results